Cite
HARVARD Citation
Pitisuttithum, P. et al. (2022). Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial. EClinicalMedicine. p. . [Online].